SomnoMed (ASX:SOM) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:SOM SomnoMed Ltd ASX:SOM
49 GF Score
Price A$0.46
GF Value A$0.45
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is SomnoMed Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ASX:SOM vs ABT, SYK, MDT: Short Interest Comparison

For the Medical Devices subindustry, SomnoMed's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SomnoMed Short Interest vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SomnoMed's Short Interest distribution charts can be found below:

* The bar in red indicates where SomnoMed's Short Interest falls into.


ASX:SOM
49GF Score
SomnoMed Ltd ASX:SOM
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SomnoMed (ASX:SOM) Overvalued in 2026?

Based on GuruFocus' analysis, SomnoMed stock appears to be overvalued. The current stock price of A$0.46 is trading 2.2% above its estimated GF Value™ of A$0.45. GuruFocus considers SomnoMed to be Fairly Valued.

Key valuation signals for ASX:SOM:

  • Short Interest:
  • GF Value™: A$0.45 vs. price of A$0.46 (2.2% above fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the ASX:SOM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SomnoMed Business Description

Other Exchanges SOMNF:USARJV:Germany
Address 20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065
SomnoMed Ltd provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is engaged in commercializing SomnoDent Mandibular Advancement Splint (MAS) and other oral devices for sleep-related disorders in Australia and overseas. The other products in the company's portfolio include SomMorning Repositioner; SomnoBrux splint, a custom-fit, acrylic splint (dental guard) for upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs cleaning tablets that have been developed to clean oral appliances. Geographically, the company generates maximum revenue from Europe, followed by North America and the Asia Pacific region.
49GF Score

Get the complete analysis for ASX:SOM

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.46
Price
A$0.45
GF Value